Literature DB >> 24235289

Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function.

Flore Duranton1, Ulrika Lundin, Nathalie Gayrard, Harald Mischak, Michel Aparicio, Georges Mourad, Jean-Pierre Daurès, Klaus M Weinberger, Angel Argilés.   

Abstract

BACKGROUND AND OBJECTIVES: Patients with CKD display altered plasma amino acid profiles. This study estimated the association between the estimated GFR and urinary and plasma amino acid profiles in CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Urine and plasma samples were taken from 52 patients with different stages of CKD, and plasma samples only were taken from 25 patients on maintenance hemodialysis. Metabolic profiling was performed by liquid chromatography coupled with tandem mass spectrometry after phenylisothiocyanate derivatization.
RESULTS: Most plasma amino acid concentrations were decreased in hemodialysis patients, whereas proline, citrulline, asparagine, asymmetric dimethylarginine, and hydroxykynurenine levels were increased (P<0.05). Both plasma levels and urinary excretion of citrulline were higher in the group of patients with advanced CKD (CKD stages 2 and 3 versus CKD stages 4 and 5; in plasma: 35.9±16.3 versus 61.8±23.6 µmol/L, P<0.01; in urine: 1.0±1.2 versus 7.1±14.3 µmol/mol creatinine, P<0.001). Plasma asymmetric dimethylarginine levels were higher in advanced CKD (CKD stages 2 and 3, 0.57±0.29; CKD stages 4 and 5, 1.02±0.48, P<0.001), whereas urinary excretion was lower (2.37±0.93 versus 1.51±1.43, P<0.001). Multivariate analyses adjusting on estimated GFR, serum albumin, proteinuria, and other covariates revealed associations between diabetes and plasma citrulline (P=0.02) and between serum sodium and plasma asymmetric dimethylarginine (P=0.03). Plasma tyrosine to phenylalanine and valine to glycine ratios were lower in advanced CKD stages (P<0.01).
CONCLUSION: CKD patients have altered plasma and urinary amino acid profiles that are not corrected by dialysis. Depending on solutes, elevated plasma levels were associated with increased or decreased urinary excretion, depicting situations of uremic retention (asymmetric dimethylarginine) or systemic overproduction (citrulline). These results give some insight in the CKD-associated modifications of amino acid metabolism, which may help improve their handling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24235289      PMCID: PMC3878706          DOI: 10.2215/CJN.06000613

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  29 in total

1.  Are supplemented low-protein diets nutritionally safe?

Authors:  M Aparicio; P Chauveau; C Combe
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

Review 2.  Review on uremic toxins: classification, concentration, and interindividual variability.

Authors:  Raymond Vanholder; Rita De Smet; Griet Glorieux; Angel Argilés; Ulrich Baurmeister; Philippe Brunet; William Clark; Gerald Cohen; Peter Paul De Deyn; Reinhold Deppisch; Beatrice Descamps-Latscha; Thomas Henle; Achim Jörres; Horst Dieter Lemke; Ziad A Massy; Jutta Passlick-Deetjen; Mariano Rodriguez; Bernd Stegmayr; Peter Stenvinkel; Ciro Tetta; Christoph Wanner; Walter Zidek
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

Review 3.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

4.  Metabolomic profiling of uremic solutes in CKD patients.

Authors:  Takafumi Toyohara; Yasutoshi Akiyama; Takehiro Suzuki; Yoichi Takeuchi; Eikan Mishima; Masayuki Tanemoto; Ayako Momose; Naoko Toki; Hiroshi Sato; Masaaki Nakayama; Atsushi Hozawa; Ichiro Tsuji; Sadayoshi Ito; Tomoyoshi Soga; Takaaki Abe
Journal:  Hypertens Res       Date:  2010-07-08       Impact factor: 3.872

5.  Consequences of renal mass reduction on amino acid and biogenic amine levels in nephrectomized mice.

Authors:  M Al Banchaabouchi; B Marescau; R D'Hooge; S Engelborghs; P P De Deyn
Journal:  Amino Acids       Date:  2000       Impact factor: 3.520

6.  Metabolism of urea cycle intermediates in chronic renal failure.

Authors:  M E Swendseid; M Wang; I Schutz; J D Kopple
Journal:  Am J Clin Nutr       Date:  1978-09       Impact factor: 7.045

7.  Enhanced degradation of tryptophan in patients on hemodialysis.

Authors:  P Koenig; C Nagl; G Neurauter; H Schennach; G Brandacher; D Fuchs
Journal:  Clin Nephrol       Date:  2010-12       Impact factor: 0.975

8.  Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.

Authors:  Yoshiharu Tsubakihara; Yoshitsugu Takabatake; Kazumasa Oka; Tatsuya Shoji; Masaki Togawa; Noriyuki Okada; Ito Takahito; Enyu Imai
Journal:  Am J Kidney Dis       Date:  2003-03       Impact factor: 8.860

9.  The significance and mechanism of an increased serum phenylalanine-tyrosine ratio during infection.

Authors:  R W Wannemacher; A S Klainer; R E Dinterman; W R Beisel
Journal:  Am J Clin Nutr       Date:  1976-09       Impact factor: 7.045

10.  Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition.

Authors:  J T Kielstein; S Simmel; S M Bode-Böger; H J Roth; H Schmidt-Gayk; H Haller; D Fliser
Journal:  Kidney Blood Press Res       Date:  2004-06-03       Impact factor: 2.687

View more
  63 in total

Review 1.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

2.  1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics.

Authors:  Gesiane Tavares; Gabriela Venturini; Kallyandra Padilha; Roberto Zatz; Alexandre C Pereira; Ravi I Thadhani; Eugene P Rhee; Silvia M O Titan
Journal:  Metabolomics       Date:  2018-02-27       Impact factor: 4.290

3.  Metabolite markers of incident CKD risk.

Authors:  Eugene P Rhee; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 8.237

4.  Reduction of carbamylated albumin by extended hemodialysis.

Authors:  Jeffrey Perl; Sahir Kalim; Ron Wald; Marc B Goldstein; Andrew T Yan; Nazanin Noori; Mercedeh Kiaii; Julia Wenger; Christopher Chan; Ravi I Thadhani; S Ananth Karumanchi; Anders H Berg
Journal:  Hemodial Int       Date:  2016-06-21       Impact factor: 1.812

5.  Associations of Plasma Amino Acid and Acylcarnitine Profiles with Incident Reduced Glomerular Filtration Rate.

Authors:  Feijie Wang; Liang Sun; Qi Sun; Liming Liang; Xianfu Gao; Rongxia Li; An Pan; Huaixing Li; Yueyi Deng; Frank B Hu; Jiarui Wu; Rong Zeng; Xu Lin
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

6.  Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease.

Authors:  Kevin T Bush; Prabhleen Singh; Sanjay K Nigam
Journal:  JCI Insight       Date:  2020-04-09

7.  Asymmetric dimethylarginine, erythropoietin resistance, and anemia in CKD.

Authors:  Tammy L Sirich; Glenn M Chertow
Journal:  Ann Transl Med       Date:  2019-07

Review 8.  An overview of renal metabolomics.

Authors:  Sahir Kalim; Eugene P Rhee
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

9.  Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease.

Authors:  Julia Z Xu; Melanie E Garrett; Karen L Soldano; Sean T Chen; Clary B Clish; Allison E Ashley-Koch; Marilyn J Telen
Journal:  Am J Hematol       Date:  2018-09-27       Impact factor: 10.047

10.  Urinary excretion of polyols and sugars in children with chronic kidney disease.

Authors:  Koen Vanlede; Leo A J Kluijtmans; Leo Monnens; Elena Levtchenko
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.